Fabry disease: enzyme replacement therapy
in [alpha]-galactosidase A deficient mice.
Enzyme replacement therapy
increases the hemoglobin concentration to almost normal levels in 6-12 months.
MYDICAR is a genetically targeted enzyme replacement therapy
intended to restore levels of SERCA2a, a regulator of calcium cycling and contractility.
We also measured fecal elastase in samples from 5 patients with chronic pancreatitis before and during oral enzyme replacement therapy
(500-1000 U of porcine lipase x [kg.
In October 2000, BioMarin initiated a randomized, double-blind Phase I clinical trial at Children's Hospital Oakland to test the safety of rhASB at two dose levels as an enzyme replacement therapy
in six MPS-VI patients.
PHILADELPHIA -- Enzyme replacement therapy
has conquered Fabry disease, a rare, lysosomal storage disease.
You and she should discuss the possibility of enzyme replacement therapy
with her physician.
The US Food and Drug Administration (FDA) has granted approval to Ultragenyx Pharmaceutical's enzyme replacement therapy
, Mepsevii (vestronidase alfa), intended for the treatment of Mucopolysaccharidosis VII (MPS VII, Sly syndrome) in both children and adults, it was reported yesterday.
Calias will have overall responsibility for the company's new Enzyme Replacement Therapy
(ERT) programs, driving scientific milestones, enhancing the IP portfolio, overseeing new product development and contributing to the overall strategic direction of the company.
Calias will have overall responsibility for the Company s new Enzyme Replacement Therapy
(ERT) programs, achieving the scientific milestones set in the business plan, enhancing the IP portfolio, overseeing new product development and contributing to the overall strategic direction of the Company.
His family were told his life expectancy would be around 11 or 12 but he started enzyme replacement therapy
and his condition plateaued.
The merger, pending shareholder and regulatory nods, will enable Synageva to proceed with the development of its SBC-102 clinical programme, an enzyme replacement therapy
for lysosomal acid lipase (LAL) deficiency.